Opinion|Videos|August 19, 2024
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Experts discuss future directions of BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
- How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
As GLP-1 Costs Climb, Medicare Part D Plans Face a Reckoning
3
New York Experts Push for Coordinated Obesity Care Teams
4
Grocery Assistance Benefit Linked to Fewer Diabetes Complications
5